SUN 1334H|607736-84-5|SUN-1334H|3QKT19VDE2|UNII-3QKT19VDE2|4-(4-(bis(4-fluorophenyl)methyl)piperazin-1-ylbut-2-enyloxy)acetic acid|{4-[4-[Bis-(4-fluorophenyl)methyl]piperazin-1-yl]-(E)-but-2-enyloxy}acetic acid dihydrochloride|SCHEMBL1138186|SCHEMBL562392
Storage Temp
Store at 2-8°C,Desiccated
Shipped In
Wet ice
Product Description
SUN 1334H is a potent, orally active, highly selective H1 receptor antagonist, with K i of 9.7 nM.
In Vitro
SUN-1334H causes potent inhibition of histamine induced contractions of isolated guinea-pig ileum with an IC 50 (half the maximal inhibitory concentration) of 0.198 μM. In CHO-K1/hERG cells, SUN-1334H does not modulate hERG K + -currents at concentrations as high as 100 μM. SUN-1334H, cetirizine and hydroxyzine cause comparable inhibition of NLF leukocytes, IL-4 and total protein concentrations. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
SUN-1334H potently inhibits histamine-induced bronchospasm over 24 hours following oral administration and completely suppresses histamine-induced skin wheal in beagle dogs and ovalbumin-induced rhinitis in guinea pigs . In skin allergy models, SUN-1334H shows potent reduction of passive and active cutaneous anaphylactic reactions. In central nervous system side effects models, SUN-1334H, desloratadine and fexofenadine are devoid of any significant effects. MCE has not independently confirmed the accuracy of these methods. They are for reference only.